Advertising Laws: Are You Missing Key Risks?

Substantiation requirements depend on the nature of the claim. Health and safety claims require the highest level of proof, often randomized controlled trials or multiple independent studies. Performance claims (for example, our software processes data 40 percent faster) require competent testing under realistic conditions. Comparative claims (for example, better than Brand X) require head-to-head testing or clear, reliable data. Environmental or sustainability claims face increasing scrutiny under state and federal green advertising guidelines.

The key takeaway is simple: if you cannot prove it before the ad runs, do not claim it. From a practitioner's perspective, I advise clients to document their substantiation process and retain that evidence for at least three to five years. Regulatory agencies routinely request this documentation during investigations, and the absence of a clear file creates immediate liability.

The FTC and state attorneys general have broad authority to challenge advertising claims. The FTC can issue cease-and-desist orders, require corrective advertising, impose civil penalties, and seek consumer redress. State attorneys general often pursue parallel actions under state consumer protection statutes. Additionally, private litigants can sue under state unfair competition laws and false advertising statutes. The enforcement landscape is fragmented, which means a single problematic claim can trigger multiple investigations simultaneously.

Under the Lanham Act, a competitor can sue for false advertising if your claims are likely to deceive consumers and cause competitive injury. The plaintiff does not need to prove actual consumer deception; likely deception is enough. Courts examine the claim in context, consider how consumers reasonably interpret it, and evaluate whether the claim is material to purchase decisions. A competitor who believes your advertising is false has a direct path to federal court and can seek injunctive relief and damages.

New York General Business Law Section 349 prohibits deceptive advertising and unfair practices. The New York Attorney General has authority to investigate and sue for violations, and private consumers can bring class actions under this statute. New York courts interpret deceptive broadly to include any representation likely to mislead a reasonable consumer. The practical significance is that New York state claims often proceed faster than federal FTC actions and can result in substantial settlements or judgments. Many national advertisers face parallel investigations in New York and federal court simultaneously, which accelerates the need for early legal review and strategic response.

Pharmaceutical advertising must comply with FDA rules requiring fair balance between benefits and risks. Dietary supplement claims cannot claim to diagnose, treat, or cure disease without FDA approval. Financial services advertising cannot make unqualified performance guarantees. Alcohol advertising faces state-by-state restrictions on media, content, and target audience. Cannabis advertising faces federal prohibition in many contexts and state-by-state regulation where legal. Each industry has its own enforcement bodies, investigation procedures, and remedies. Non-compliance is not a minor technical violation; it is a regulatory red flag that invites investigation and escalation.